DiaMedica Therapeutics (DMAC) Expected to Announce Earnings on Wednesday

Key Points

• DiaMedica Therapeutics (DMAC) is expected to report its Q2 2025 earnings on August 6th, with analysts projecting an earnings per share (EPS) of ($0.18).
• The company's stock has recently decreased by 9.3%, with current trading around $4.59 and a market capitalization of $196.82 million.
• Major shareholder Jan Stahlberg significantly increased their stake by purchasing over 1.5 million shares, enhancing their total holdings to 6.8 million shares.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.18) EPS for the quarter, meeting analysts' consensus estimates of ($0.18). During the same quarter last year, the business posted ($0.14) EPS. On average, analysts expect DiaMedica Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

DiaMedica Therapeutics Price Performance

Shares of NASDAQ DMAC traded down $0.10 during mid-day trading on Friday, reaching $4.12. 203,997 shares of the company traded hands, compared to its average volume of 403,243. DiaMedica Therapeutics has a fifty-two week low of $3.19 and a fifty-two week high of $6.82. The firm has a market cap of $176.68 million, a PE ratio of -6.44 and a beta of 1.25. The stock has a fifty day simple moving average of $4.05 and a 200-day simple moving average of $4.63.

Wall Street Analyst Weigh In

DMAC has been the topic of a number of research analyst reports. Craig Hallum raised their price objective on shares of DiaMedica Therapeutics from $8.00 to $11.00 and gave the company a "buy" rating in a research note on Friday, July 18th. Lake Street Capital raised their target price on shares of DiaMedica Therapeutics from $11.00 to $14.00 and gave the stock a "buy" rating in a report on Friday, July 18th. Finally, HC Wainwright raised their target price on shares of DiaMedica Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a report on Friday, July 18th.

Insider Buying and Selling

In other news, major shareholder Jan Stahlberg acquired 1,542,857 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The stock was purchased at an average price of $3.50 per share, with a total value of $5,399,999.50. Following the purchase, the insider owned 6,764,465 shares of the company's stock, valued at approximately $23,675,627.50. This trade represents a 29.55% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 7.30% of the company's stock.

Hedge Funds Weigh In On DiaMedica Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DMAC. Royal Bank of Canada boosted its stake in DiaMedica Therapeutics by 46,879.1% in the 1st quarter. Royal Bank of Canada now owns 155,031 shares of the company's stock worth $588,000 after purchasing an additional 154,701 shares during the period. Jane Street Group LLC boosted its stake in shares of DiaMedica Therapeutics by 138.5% during the 1st quarter. Jane Street Group LLC now owns 100,669 shares of the company's stock valued at $382,000 after buying an additional 58,457 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in shares of DiaMedica Therapeutics by 76.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 121,802 shares of the company's stock valued at $462,000 after buying an additional 52,854 shares during the period. Institutional investors and hedge funds own 10.12% of the company's stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.